The tools ideate on Boston Scientific’s Farapulse PFA system, which contributed towards a 172% uptick in the company’s Q4 ...

Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...

Argus Research analyst David Toung maintained a Buy rating on Boston Scientific (BSX – Research Report) on February 14. The company’s shares ...

So far, BSX stock has risen 19% year-to-date. Separately, CROX reports earnings tomorrow. Will the stock pop on the news? See ...

At the town hall of the annual gathering of the American Association for the Advancement of Science, Trump’s name was largely ...

Boston Scientific announced won CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software.

Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

This page features the latest news about the Boston Scientific stock. Boston Scientific CEO sells over $13 million in company stock Boston Scientific Corporation's (NYSE:BSX) Chairman, President ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...